UBE2T knockdown inhibits gastric cancer progression

Changjiang Luo; Yunyi Yao; Zeyuan Yu; Huinian Zhou; Lingyun Guo; Junqiang Zhang; Hongtai Cao; Genyuan Zhang; Yumin Li; Zuoyi Jiao

doi:10.18632/oncotarget.15947

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2023; 14:188-189.

UBE2T knockdown inhibits gastric cancer progression

Changjiang Luo, Yunyi Yao, Zeyuan Yu, Huinian Zhou, Lingyun Guo, Junqiang Zhang, Hongtai Cao, Genyuan Zhang, Yumin Li and Zuoyi Jiao _

PDF | HTML | How to cite

Oncotarget. 2017; 8:32639-32654. https://doi.org/10.18632/oncotarget.15947

Metrics: PDF 2361 views | HTML 3724 views | ?

Abstract

Changjiang Luo1,*, Yunyi Yao2,*, Zeyuan Yu1, Huinian Zhou1, Lingyun Guo1, Junqiang Zhang1, Hongtai Cao1, Genyuan Zhang1, Yumin Li1, Zuoyi Jiao1

1Department of General Surgery, Lanzhou University Second Hospital and Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou, Gansu, 730030, China

2Department of Medical Technology and Key Laboratory of Biotechnology for Laboratory Medicine of Suzhou, Suzhou Vocational Health College, Suzhou, Jiangsu, 215009, China

*These authors contributed equally to this work

Correspondence to:

Zuoyi Jiao, email: [email protected]

Yumin Li, email: [email protected]

Keywords: UBE2T, ubiquitination, gastric cancer, tumor apoptosis, invasion and metastasis

Received: October 28, 2016 Accepted: February 22, 2017 Published: March 06, 2017

ABSTRACT

Ubiquitin-conjugating enzymes (E2 enzymes) such as UBE2T target proteins for degradation via the proteasome. Here, we examined the effects of UBE2T on the progression of gastric cancer. UBE2T was highly expressed in gastric tumors and gastric cancer cells. siRNA-mediated suppression of UBE2T inhibited gastric cancer cell proliferation and colony formation by promoting cell cycle arrest at G2/M phase and increasing apoptosis. Suppression of UBE2T also attenuated the invasive and metastatic abilities of gastric cancer cells by altering expression of epithelial-mesenchymal transition (EMT)-related factors. A xenograft model in which nude mice were injected with UBE2T knockdown human gastric cancer cells confirmed that suppression of UBE2T also decreased tumor formation and growth in vivo. Expression levels of CCND1, Phospho-GSK3B, WNT family members, and MYC were all affected by UBE2T knockdown. These results suggest that UBE2T plays a critical role in gastric cancer, and that it may serve as a useful prognostic biomarker and therapeutic target in gastric cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15947

Publication Alerts

Research Papers:

UBE2T knockdown inhibits gastric cancer progression

Abstract